Organization (Other)
BRACCO DIAGNOSTICS INC.
ClinicalTrials.gov lists BRACCO DIAGNOSTICS INC. as lead sponsor of 49 trials. It has 2 active development programs and 20 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers BRACCO DIAGNOSTICS INC.: 49 lead-sponsored trials and 1 legal-entity registration. The parent company on record for BRACCO DIAGNOSTICS INC. is BRACCO S.P.A., which does not have its own page on this site.
Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.
Disease areas (51)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Prostatic Neoplasms | 31 |
| Brain Neoplasms | 12 |
| Coronary Disease | 12 |
| Coronary Artery Disease | 9 |
| Breast Neoplasms | 5 |
Showing 5 of 51 disease areas.
Trials by start year as sponsor or collaborator (18)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2024 | 1 |
| 2021 | 2 |
| 2020 | 2 |
| 2019 | 2 |
| 2018 | 4 |
| 2017 | 2 |
| 2016 | 1 |
| 2015 | 4 |
| 2014 | 5 |
| 2012 | 2 |
Showing 10 of 18 years.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (2)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| BR55 | Ovarian Neoplasms | Phase 2 | 2 |
| BR55 | Prostatic Neoplasms | Phase 1/2 | 2 |
Approved assets (20)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Gadobenate Dimeglumine | 11 |
| Iopamidol | 6 |
| Gadobutrol | 2 |
| Iopamidol 370 mgI/mL | 2 |
| Iodixanol 320 | 2 |
Showing 5 of 20 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 25% hit target (n=8) | 50% on time (n=8) |
Journals published in (84)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Journal of nuclear medicine : official publication, Society of Nuclear Medicine | 12 |
| Neuro-oncology | 11 |
| European journal of nuclear medicine and molecular imaging | 8 |
| Radiology | 5 |
| AJNR. American journal of neuroradiology | 4 |
Showing 5 of 84 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 539 | 50 | 2025-11-04 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| VAI | 7 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| BRACCO DIAGNOSTICS INC | Princeton, US | FDA |
Organization relationships (9)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Medpace Holdings, Inc. | Uses vendor | 2 |
| Parexel | Uses vendor | 2 |
| Dragon Master Foundation | Co sponsors trial with | 2 |
| Philips Medical Systems | Co sponsors trial with | 1 |
| James Mountz | Co sponsors trial with | 1 |
Showing 5 of 9 relationships.
Latest dated events (699)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-11-29 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08-31 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-07-29 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-07-28 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 699 events.
Biomarker capability evidence (39)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| AKR1C1 | Trial collaborator | Named in trial inclusion criteria |
| DSE | Trial sponsor | Named in trial inclusion criteria |
| DSE | Trial sponsor | Named in trial inclusion criteria |
| DSE | Trial sponsor | Primary endpoint in a Phase 3 trial |
| KLK3 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 39 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda recalls, fda import refusals, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.